Artificial Intelligence & Machine Learning
…
Together, we've formed the Translational Oncology Research Hub with King’s College London to provide insight into how patients respond to cancer treatment, using novel machine learning to analyse high-risk patients, integrating genetic and molecular traits, and ultimately make better predictions for better outcomes.
This is just one way we’re looking to expand the scale,…
Late last year, Open AI's ChatGPT introduced the wider world to the immense power of artificial intelligence (AI). However, pharmaceutical companies have been experimenting with various forms of next-generation AI since the middle of the last decade. These AI systems can help accelerate drug discovery, optimize clinical trials, and improve patient outcomes. This tool opens…
A GSK-funded paper on pharmacovigilance stated that the pharma industry needs to harness the properties of data to allow optimal use of AI, otherwise “we will fail to do all we can for patient safety”.
According to a recent review funded by GSK Biologicals, artificial intelligence (AI) and machine learning (ML) seems intuitively, to be…
Good morning, More from Fortune: 5 side hustles where you may earn over $20,000 per year—all while working from home Looking to make extra cash? This CD has a 5.15% APY right now Buying a house? Here's how much to save This is how much money you need to earn annually to comfortably buy a…
GSK CEO Emma Walmsley was our guest this week on Fortune‘s Leadership Next podcast. She showed up in person at the Fortune offices in New York for the occasion, and the fascinating interview that followed proved again that in-person conversations are, well, just better than the largely remote ones we’ve been doing since the weekly podcast’s…
PathAI is partnering with GSK on a randomised Phase IIb trial in non-alcoholic steatohepatitis (NASH). The Boston based artificial intelligence (AI)-powered pathology company will be responsible for generating, digitising, and analysing liver biopsy slides for central pathologist evaluation.
In addition, its AI-based Measurement of NASH Histology (AIM-NASH) tool will be used for histological evaluation. The…
Part of Multi-year Partnership Focusing on Drug Development in NASH and Oncology
BOSTON , March 30, 2023 /PRNewswire/ -- PathAI, a leading provider of AI-powered pathology, today announced its partnership with GSK (LSE/NYSE: GSK) on HORIZON, a randomized Phase 2b non-alcoholic steatohepatitis (NASH) clinical trial (NCT05583344). The trial will measure improvements in…
Mike Montello recalls being fascinated with space exploration as a child. But rather than pursuing work with NASA, his career path took him into drug research and he is now GSK’s senior vice president, R&D digital and tech. Still, he sees connections between his work and the endeavors producing new celestial discoveries.
New images from…
Courtesy of Leon Neal/Getty Images
In an effort to expand its footprint in the AI space, GSK announced Tuesday it has struck a $70 million deal with Tempus in exchange for expanded access to Tempus’ AI-based patient data platform.
Under the terms of the deal, GSK will have access to Tempus’ de-identified patient data drawn from…
The head of artificial intelligence and machine learning at GSK believes the advanced technologies are on course to make drug research and development the most productive in the group’s 307-year history. The newly focused FTSE 100 pharmaceuticals group is seeking to revive its pipeline after lengthy criticism of its productivity and its share price. GSK…